All News

Dec
5
2022

Two of AcouSort’s board members and CEO acquire shares

AcouSort AB (publ) (“AcouSort” or the “Company”) today announces that founders and board members Thomas Laurell and Stefan Scheding as well as CEO Torsten Freltoft have acquired shares in the

Read More
Dec
1
2022

The BioWings project creates new opportunities for large-scale production and exosome-based diagnostics

AcouSort and its collaborators are now finishing the 4-year BioWings project which has developed new thin-film materials generating the ultrasound necessary to move cells in AcouSort’s chips. The new materials

Read More
Nov
24
2022

AcouSort presents at Stora Aktiedagen in Stockholm, November 30, addressing current developments in the vibrant cell therapy space

On November 30, 2022, CEO Torsten Freltoft will present at Stora Aktiedagen in Stockholm. In his presentation, Torsten will talk about the company’s continuous advancements in the cell therapy space,

Read More
Nov
23
2022

AcouSort Interim Report Q3, 2022

Regulatory

Today, November 23, 2022, AcouSort is releasing its Interim Report for Q3, 2022. The report is available both in Swedish and English and can be found here AcouSort AB Q3

Read More
Nov
14
2022

AcouSort expands its cell therapy efforts and enters collaboration with global life science company

Regulatory

Cell therapy is an area where AcouSort sees great potential for the company’s technology. Initially, AcouSort aims at enabling the automation of cell therapy preparation with its AcouWash technology. In

Read More
Nov
11
2022

AcouSort to supply Lund University with unique pre-focusing technology to enable high precision cell separation

AcouSort has received an order from Lund University to develop and deliver a modified AcouWash2 system with a unique pre-focusing feature to enable high precision cell separation of circulating tumor

Read More
Oct
21
2022

AcouSort travels to Japan to re-ignite marketing efforts as the country opens up after the pandemic

AcouSort has been established on the Japanese market since 2019 when the company signed an exclusive distribution agreement with its Japanese partner Physio-Tech. The same year AcouSort also initiated a

Read More
Oct
14
2022

AcouSort’s role in the Blue4Therapy project expands – SEK 700,000 in additional revenue in 2022

The Blue4Therapy project was initiated in May 2020 with the ambition to develop clinical applications in cell therapy and stem cell treatments – two areas with great commercial potential. Behind

Read More
Sep
9
2022

AcouSort selected by EIC for participation at MEDICA, Europe’s leading medical exhibition

AcouSort has been selected by the European Innovation Council (EIC) for participation at MEDICA 2022 after a highly competitive evaluation process. AcouSort is thus one of the 20 companies selected

Read More
Aug
24
2022

AcouSort Interim report Q2, 2022

Regulatory

Today, August 24, 2022, AcouSort is releasing its Interim Report for Q2, 2022. The report is available both in Swedish and English and can be found here Interim Report Q2

Read More